Patents by Inventor Stephen Johnstone

Stephen Johnstone has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8796216
    Abstract: The present invention relates to a method for suppressing neuroendocrine disease. The therapy employs use of a non-cytotoxic protease, which is targeted to a neuroendocrine tumor cell, preferably via a somatostatin or cortistatin receptor, a GHRH receptor, a ghrelin receptor, a bombesin receptor, a urotensin receptor a melanin-concentrating hormone receptor 1; a KiSS-1 receptor or a prolactin-releasing peptide receptor. When so delivered, the protease is internalized and inhibits secretion from said tumor cell. The present invention also relates to polypeptides and nucleic acids for use in said methods.
    Type: Grant
    Filed: December 16, 2010
    Date of Patent: August 5, 2014
    Assignee: Syntaxin Limited
    Inventors: Stephen Johnstone, Philip Marks, Keith Foster
  • Publication number: 20110171191
    Abstract: The present invention relates to a method for suppressing neuroendocrine disease. The therapy employs use of a non-cytotoxic protease, which is targeted to a neuroendocrine tumour cell, preferably via a somatostatin or cortistatin receptor, a GHRH receptor, a ghrelin receptor, a bombesin receptor, a urotensin receptora melanin-concentrating hormone receptor 1; a KiSS-1 receptor or a prolactin-releasing peptide receptor. When so delivered, the protease is internalised and inhibits secretion—from said tumourcell. The present invention also relates to polypeptides and nucleic acids for use in said methods.
    Type: Application
    Filed: June 11, 2009
    Publication date: July 14, 2011
    Applicant: SYNTAXIN LIMITED
    Inventors: Stephen Johnstone, Philip Marks, Keith Foster
  • Publication number: 20110160135
    Abstract: The present invention relates to a method for suppressing neuroendocrine disease. The therapy employs use of a non-cytotoxic protease, which is targeted to a neuroendocrine tumour cell, preferably via a somatostatin or cortistatin receptor, a GHRH receptor, a ghrelin receptor, a bombesin receptor, a urotensin receptor a melanin-concentrating hormone receptor 1; a KiSS-1 receptor or a prolactin-releasing peptide receptor. When so delivered, the protease is internalised and inhibits secretion from said tumour cell. The present invention also relates to polypeptides and nucleic acids for use in said methods.
    Type: Application
    Filed: December 16, 2010
    Publication date: June 30, 2011
    Applicant: SYNTAXIN LIMITED
    Inventors: Stephen JOHNSTONE, Philip MARKS, Keith FOSTER
  • Publication number: 20080226693
    Abstract: The apparatus and method for preparing a polymeric structure from which a number of medical devices may be constructed is described. The structures are preferably formed from bioabsorbable materials using low temperature fabrication processes, whereby drugs or other bio-active agents are incorporated into or onto the device and degradation of the drugs or other agents during processing is minimized. The method includes preparing a solution of at least one bioabsorbable polymer and a solvent. The solution is then deposited onto a stage and converted into a structure. The solvent is evaporated from the structure. The dried solution forms a structure that is removed from the stage and further dried before being stored in an inert environment. Thereafter, a medical device such as a stent may be constructed from the structure.
    Type: Application
    Filed: March 14, 2007
    Publication date: September 18, 2008
    Inventors: Vipul Bhupendra Dave, David Cook, Brian R. White, Stephen Johnstone, Jacob Leidner